ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,749.00
0.35%
S&P ASX All Technology
3,067.50
0.14%
Brent Oil
84.005
0.07%
US Dollar vs AUD
1.51334
0.17%
Bitcoin
62,874.49
-0.28%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Bergenbio Asa (0RU5)

  7. Bergenbio Asa (0RU5) News

0RU5

Bergenbio Asa (0RU5)

Bergenbio Asa
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0RU5
DateTimeSourceHeadlineSymbolCompany
22/08/202318:50PR Newswire (US)BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung CancerLSE:0RU5Bergenbio Asa
22/08/202318:45PR Newswire (US)BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung CancerLSE:0RU5Bergenbio Asa
26/05/202323:07PR Newswire (US)BerGenBio ASA: Approval and publication of prospectus for the preferential Rights IssueLSE:0RU5Bergenbio Asa
26/04/202302:26PR Newswire (US)BerGenBio ASA: Proposed partially underwritten rights issueLSE:0RU5Bergenbio Asa
18/04/202315:23PR Newswire (US)BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACRLSE:0RU5Bergenbio Asa
18/04/202315:20PR Newswire (US)BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACRLSE:0RU5Bergenbio Asa
09/03/202321:22PR Newswire (US)BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 MutationsLSE:0RU5Bergenbio Asa
09/03/202321:20PR Newswire (US)BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 MutationsLSE:0RU5Bergenbio Asa
16/02/202317:32PR Newswire (US)BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business UpdateLSE:0RU5Bergenbio Asa
16/02/202317:30PR Newswire (US)BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business UpdateLSE:0RU5Bergenbio Asa
16/02/202303:35PR Newswire (US)BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC PatientsLSE:0RU5Bergenbio Asa
16/02/202303:31PR Newswire (US)BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC PatientsLSE:0RU5Bergenbio Asa
02/02/202317:17PR Newswire (US)BerGenBio Announces the Establishment of Oncology Scientific Advisory BoardLSE:0RU5Bergenbio Asa
02/02/202317:15PR Newswire (US)BerGenBio Announces the Establishment of Oncology Scientific Advisory BoardLSE:0RU5Bergenbio Asa
15/11/202217:10PR Newswire (US)BerGenBio reports third quarter 2022 financial results and provides business updateLSE:0RU5Bergenbio Asa
15/11/202217:07PR Newswire (US)BerGenBio reports third quarter 2022 financial results and provides business updateLSE:0RU5Bergenbio Asa
25/10/202216:37PR Newswire (US)BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva ASLSE:0RU5Bergenbio Asa
25/10/202216:34PR Newswire (US)BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva ASLSE:0RU5Bergenbio Asa
11/10/202216:36PR Newswire (US)BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 MutationsLSE:0RU5Bergenbio Asa
11/10/202216:34PR Newswire (US)BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 MutationsLSE:0RU5Bergenbio Asa
27/09/202223:31PR Newswire (US)BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTSLSE:0RU5Bergenbio Asa
27/09/202223:28PR Newswire (US)BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTSLSE:0RU5Bergenbio Asa
23/08/202215:36PR Newswire (US)BerGenBio reports second quarter and half year 2022 financial results and provides business updateLSE:0RU5Bergenbio Asa
23/08/202215:34PR Newswire (US)BerGenBio reports second quarter and half year 2022 financial results and provides business updateLSE:0RU5Bergenbio Asa
04/05/202215:29PR Newswire (US)BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19LSE:0RU5Bergenbio Asa
04/05/202215:27PR Newswire (US)BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19LSE:0RU5Bergenbio Asa
26/04/202215:13PR Newswire (US)BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT METLSE:0RU5Bergenbio Asa
26/04/202215:12PR Newswire (US)BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT METLSE:0RU5Bergenbio Asa
11/04/202215:12PR Newswire (US)BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical OfficerLSE:0RU5Bergenbio Asa
07/04/202222:20PR Newswire (US)BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021LSE:0RU5Bergenbio Asa
 Showing the most relevant articles for your search:LSE:0RU5

Your Recent History

COIN
ETHUSD
Ethereum
CCOM
SILVER
SILVER
ASX
XFL
S&P ASX 50
ASX
TLS
Telstra
ASX
WPL
Woodside Petroleum
NASDAQ
NVDA
NVIDIA
ASX
FMG
Fortescue
FX
AUDCAD
AUD vs CAD
ASX
WOW
Woolworths
NYSE
JPM
JP Morgan Chase
ASX
ANZ
Australia And New Zealan...
FTSE
UKX
FTSE 100
NYSE
XOM
Exxon Mobil
ASX
XJO
S&P ASX 200
ASX
SUN
Suncorp
ASX
BHP
BHP
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved